Chronic stable angina pectoris

Preview

In most patients with stable angina pectoris, symptoms can be controlled successfully with drug therapy. Revascularization procedures should be reserved for those at high risk for cardiac events and those who do not respond to optimal therapy with any of the three classes of antianginal agents. In this article, the authors describe tailoring of medical therapy on the basis of concomitant disease, outcome of risk stratification, and response to individual agents.

Additional information

Notes on contributors

Udho Thadani

Udho Thadani, MBBS, MRCP, FRCPC Dr Thadani is professor of medicine, director of clinical research, and vice chief, cardiology section, University of Oklahoma College of Medicine, Oklahoma City. His research interests include ischemic heart disease and pharmacotherapy of angina pectoris.

Asim Chohan

Asim Chohan, MBBS Dr Chohan is a fourth-year fellow in interventional cardiology, University of Oklahoma College of Medicine.